CLDF Title
Home | Contact Us | Bookmark
    HCC   HE   HRS   NASH   PBC   THROMBOCYTOPENIA  
Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library CLDF 2019 Year in Review Conference Highlights
 
Back  
 
Reuters Health Information: Many patients with NAFLD should be screened for liver cancer, experts say

Many patients with NAFLD should be screened for liver cancer, experts say

Last Updated: 2020-02-07

By Reuters Staff

NEW YORK (Reuters Health) - Screening and surveillance for hepatocellular carcinoma (HCC) is important in many patients with nonalcoholic fatty liver disease (NAFLD), according to an expert panel of the American Gastroenterological Association (AGA).

"The incidence of NAFLD-related HCC is increasing in the United States," Dr. Rohit Loomba, director of the NAFLD Research Center at the University of California, San Diego, in La Jolla, and colleagues note in Gastroenterology.

"Despite this rise in the incidence, screening and surveillance for HCC among patients at risk of developing HCC is suboptimal in general, and is disproportionately lower in patients with NAFLD-related HCC. Therefore, there is a major unmet need to provide clear best practice advice to clinicians regarding risk assessment of HCC among patients with NAFLD and appropriate screening and surveillance strategies," they write.

Following an evidenced-based review addressing HCC risk in patients with NAFLD, the panel developed the following "Best Practice Advice" statements to guide clinical management:

1: Screening for HCC should be considered in all patients with cirrhosis due to NAFLD.

2: Patients with NAFLD with non-invasive markers showing evidence of advanced liver fibrosis or cirrhosis should be considered for HCC screening.

3: Patients with NAFLD in the absence of advanced liver fibrosis should not be routinely considered for HCC screening.

4: Adequacy of ultrasound in assessing the liver parenchyma for mass lesions should be documented when used for HCC screening in patients with cirrhosis due to NAFLD.

5: When the quality of ultrasonography is sub-optimal for screening of HCC (e.g., due to obesity) future screening should be performed by either CT or MRI scan, with or without AFP, every six months.

6: Patients with cirrhosis due to NAFLD should be counseled on abstaining from alcohol and tobacco.

7: Optimal management of diabetes and dyslipidemia through lifestyle modification and pharmacotherapy is encouraged in patients with NAFLD and advanced liver fibrosis who are at risk for HCC.

8: Optimal management of obesity through lifestyle modification, pharmacotherapy or endoscopic or surgical bariatric procedures is encouraged in patients with NAFLD and advanced liver fibrosis who are at risk for HCC.

Dr. Loomba serves on the steering committee of the REGENERATE Trial funded by Intercept Pharmaceuticals, is a co-founder of Liponexus Inc and serves as a consultant or advisory board member for several pharmaceutical companies.

Dr. Loomba did not respond to a request for comment by press time.

SOURCE: http://bit.ly/3ba3kCq Gastroenterology, online January 29, 2020.

 
 
 
 
                               
 
HEPATITIS
HBV
HCV
HDV
 
 
HCC
Slide Library
Abstract Library
 
HE
Webcasts
Slide Library
Abstract Library
 
HRS
Webcasts
Slide Library
Abstract Library
 
NASH
Webcasts
Slide Library
Abstract Library
 
 
PBC
Webcasts
Slide Library
Abstract Library
 
 
THROMBOCYTOPENIA
Webcasts
Slide Library
   
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors/Faculty
2019 GI Fellow Board of Advisors
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
             
CLDF Follow Us
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2020 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.